Prolongation of survival of mice with glioma treated with semiallogeneic fibroblasts secreting interleukin-2

Neurosurgery

Volumn 45, Issue 4, 1999, Pages 867-874

  Click, Roberta P ^a   Lichtor, Terry ^b   De Zoeten, Edwin ^c   Deshmukh, Praveen ^d   Cohen, Edward P ^e  

^a Jr Hospital of Cook County   (United States)

^b LOYOLA UNIVERSITY   (United States)

^c Department of Anatomy and Cell Biology ^*  (United States)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^e UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

Fibroblasts; Gene therapy; Glioma; Immunotherapy; Interleukin 2; Semiallogeneic; Tumor vaccine

Indexed keywords

INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CONTROLLED STUDY; CYTOKINE RELEASE; FIBROBLAST; GLIOMA; IMMUNOCYTOTOXICITY; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; TREATMENT OUTCOME;

ANIMALS; BRAIN NEOPLASMS; CELL TRANSPLANTATION; FEMALE; FIBROBLASTS; GENE THERAPY; GLIOMA; IMMUNOTHERAPY; INTERLEUKIN-2; KILLER CELLS, LYMPHOKINE-ACTIVATED; KILLER CELLS, NATURAL; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS;

EID: 0032833120     PISSN: 0148396X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006123-199910000-00028     Document Type: Article

References (25)

1. Barba D, Saris SC, Holder C, Rosenberg SA, Oldfield EH Intratumoral LAK cell and interleukin-2 therapy of human gliomas. J Neurosurg 70 : 175-182,1989.
2. Colbere-Garapin F, Horodniceanu F, Kourilsky P, Garapin AC A new dominant hybrid selective marker for higher eukaryotic cells. J Mol Biol 150 : 1-14, 1981.
3. de Zoeten EF, Carr-Brendel V, Cohen EP Resistance to melanoma in mice immunized with semiallogeneic fibroblasts transfected with DNA from mouse melanoma cells. J Immunol 160 2915-2922,1998.
4. Fearon ER, Itaya T, Hunt B, Vogelstein B, Frost P Induction in a murine tumor of immunogeneic tumor variants by transfection with a foreign gene. Cancer Res 48 : 2975-2980, 1988.
5. Click RP, Lichtor T, Kim TS, Ilangovan S, Cohen EP Fibroblasts genetically engineered to secrete cytokines suppress tumor growth and induce antitumor immunity to a murine glioma in vivo. Neurosurgery 36 548-555,1995.
6. Click RP, Lichtor T, Mogharbel A, Taylor ÇA, Cohen EP Intracerebral versus subcutaneous immunization with allogeneic fibroblasts genetically engineered to secrete interleukin-2 in the treatment of central nervous system glioma and melanoma. Neurosurgery 41 : 898-907,1997.
7. Griffitt VV, Click RP, Lichtor T, Cohen EP Survival and toxicity of an allogeneic vaccine in the central nervous system. Neurosurgery 42 : 335-340, 1998.
8. Hui KM, Sim TF, Foo TT, Oei AA Tumor rejection mediated by transfection with allogeneic class I histocompatibility gene. J Immunol 143 : 3835-3843, 1989.
9. Kim TS, Russell SJ, Collins MKL, Cohen EP Immunity to B16 melanoma in mice immunized with IL-2-secreting allogeneic mouse fibroblasts expressing melanoma-associated antigens. Int J Cancer 51 283-289, 1992.
10. Kündig TM, Bachmann MF, DiPaolo C, Simard JJ, Battegay M, Lother H, Gessner A, Kühlcke K, Ohashi PS, Hengartner H, Zinkemagel RM Fibroblasts as efficient antigen-presenting cells in lymphoid organs. Science 268 : 1343-1347, 1995.
11. Lichtor T, Click RP, Kim TS, Hand R, Cohen EP Prolonged survival of mice with glioma injected intracerebrally with double cytokine-secreting cells. J Neurosurg 83 : 1038-1044, 1995.
12. Mahaley MS Jr, Mlettlin C, Natarajan N, Laws ER Jr, Peace BB National survey of patterns of care for brain-tumor patients. J Neurosurg 71 : 826-836, 1989.
13. Markowitz D, Goff S, Bank A Construction and use of a safe and efficient amphotropic packaging cell line. Virology 167 : 400-406, 1988.
14. Merchant RE, Ellison MD, Young HF Immunorherapy for malignant glioma using human recombinant interleukin-2 and activated autologous lymphocytes A review of pre-clinical and clinical investigations. J Neurooncol 8 173-188, 1990.
15. Merchant RE, McVicar DW, Merchant LH, Young HF Treatment of recurrent malignant glioma by repeated intracerebral injections of human recombinant interleukin-2 alone or in combination with systemic interferon-a Results of a phase I clinical trial. J Neurooncol 12 75-83, 1992.
16. Ostrand-Rosenberg S, Thakur A, Clements V Rejection of mouse sarcoma cells after transfection of MHC class genes. J Immunol 144 : 4068-4071, 1990.
17. Ram Z, Walbridge S, Heiss JD, Culver KVV, Blaese RM, Oldfield EH In vivo transfer of the human interleukin-2 gene Negative tumoricidal results in experimental brain tumors. J Neurosurg 80 535-540,1994.
18. Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan VVM, Robertson CN, Lee RE, Rubin JT, Seipp CA, Simpson CG, White DE A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316 889-897, 1987.
19. Rosenberg SA, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, Seipp CA, Einhorn JH, White DE Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 271 907-913,1994.
20. Roszman T, Elliott L, Brooks W Modulation of T-cell function by gliomas. Immunol Today 12 : 370-374, 1991.
21. Schoenberger SP, Jonges LE, Mooijaart RJD, Hartgers F, Toes REM, Kast WM, Melief CJM, Offringa R Efficient direct priming of tumor-specific cytotoxic T lymphocytes in vivo by an engineered APC. Cancer Res 58 3094-3100,1998.
22. Tjuvajev J, Gansbacher B, Desai R, Beattie B, Kaplitt M, Matei C, Koutcher J, Gilboa E, Blasberg R RG-2 glioma growth attenuation and severe brain edema caused by local production of interleukin-2 and interferon-y. Cancer Res 55 1902-1910,1995.
23. Watts RG, Wright JL, Atkinson LL, Merchant RE Histopathological and blood-brain barrier changes in rats induced by intracerebral injection of human recombinant interleukin 2. Neurosurgery 25 202-208, 1989.
24. Yamada G, Kitamura Y, Sonoda H, Harada H, Taki S, Mulligan RC, Osawa H, Diamantstein T, Yokoyama S, Taniguchi T Retroviral expression of the human IL-2 gene in a murine T cell line results in cell growth autonomy and tumorigenicity. EMBO J 6 2705-2709, 1987.
25. Zhang RD, Price JE, Fujimaki T, Bucana CD, Fidler IJ Differential permeability of the blood brain barrier in experimental brain métastases produced by human neoplasms implanted into nude mice. Am J Pathol 141 : 1115-1124, 1992.